Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Email

Nutrition Intervention Trials in Linxian, China

photograph of two men, one undergoing esophageal cytology with a balloon.

Professor Shen Qiong, the inventor of the Chinese esophageal cytology balloon and the father of Chinese balloon cytology, inserting his balloon into Sandy Dawsey on his first day in Linxian, China in October 1987.

The Nutrition Intervention Trials (NIT) were launched in 1985 as randomized controlled trials which tested the effects of multiple vitamin and mineral interventions on total mortality and total and cause-specific cancer mortality in a rural Chinese population. The original goal of the NIT was to evaluate the role of nutrition in the etiology and prevention of upper gastrointestinal cancers in over 32,000 residents in Linxian, China. With the conclusion of the intervention phase in 1991, and the determination that the micronutrient combination of selenium/vitamin E/ß-carotene reduced total mortality, total cancer mortality, and gastric cancer mortality, objectives now include: 

  • Determination of post-trial effects of the interventions; 
  • Evaluation of etiologic hypotheses, including nutrition, carcinogens, infections, genetics, and other exposures; 
  • Studies of natural history; and 
  • Examination of interactions (gene-environment, gene-gene, and gene-intervention).

In collaboration with the Cancer Institute of the Chinese Academy of Medical Sciences in Beijing, DCEG investigators continue to follow trial participants to ascertain endpoints, conduct nested case-control and case-cohort studies using baseline serum, and perform expanded DNA and biochemical analyses on additional blood samples collected during follow-up. To date, investigators have accrued almost 3,500 esophageal squamous cell carcinoma cases and over 2,500 gastric adenocarcinoma cases among the original 32,000 subjects.

For more information, contact Christian Abnet.

Metabolic Epidemiology Branch - Research Areas

Email